4basebio (LON:4BB – Get Free Report) issued its earnings results on Monday. The company reported GBX (0.57) EPS for the quarter, Digital Look Earnings reports.
4basebio Price Performance
Shares of LON 4BB traded down GBX 2.70 during trading on Tuesday, hitting GBX 559.80. The company had a trading volume of 261 shares, compared to its average volume of 1,353. The company has a market cap of £86.69 million, a P/E ratio of -5.14 and a beta of 1.09. The company has a debt-to-equity ratio of 201.47, a quick ratio of 3.52 and a current ratio of 2.73. The business’s 50-day moving average is GBX 511.05 and its 200 day moving average is GBX 510.01. 4basebio has a 52 week low of GBX 420 and a 52 week high of GBX 820.
Analyst Ratings Changes
Separately, Royal Bank Of Canada cut their price target on 4basebio from GBX 1,600 to GBX 1,400 and set an “outperform” rating on the stock in a report on Monday, June 15th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of GBX 1,400.
4basebio Company Profile
4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.
Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.
Further Reading
- Five stocks we like better than 4basebio
- Why SpaceX Investors Should Look Past Starship’s Fiery Splashdown
- Meta’s Muse Is Taking Aim at E-Commerce, But Amazon Isn’t Playing Along
- NVIDIA Just Strengthened the Case for Its Massive Stock Price Upside
- Apple, Meta, and SpaceX Are Driving a Device Boom—These 3 Stocks Could Benefit
Receive News & Ratings for 4basebio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4basebio and related companies with MarketBeat.com's FREE daily email newsletter.
